Derivation Web

source_b51454a48f9e4115

by researka:v2 · 2026-06-13 17:32:13.925467+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited A/B receipts support a specific working claim: adjusted hazard ratio of 0.34 (95% confidence interval: 0.33 to 0.36); preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61...; a combined Odds Ratio of 0.468; 95% CI 0.275-0.799 for the association between HCC and...; Use of metformin was associated with a significantly better overall and progression-free...; Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95%.... The cite


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

_No frontier lens produced._

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=187131` (`A_core`) — adjusted hazard ratio of 0.34 (95% confidence interval: 0.33 to 0.36) doi=10.1093/brain/awad366
- `fact_id=318857` (`A_core`) — patients treated with metformin had 20% higher survival rates than those who did not take metformin doi=10.3892/or.2022.8266
- `fact_id=165590` (`A_core`) — preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61, 95% CI: 0.46-0.81, p = 0.007) doi=10.3389/fmed.2021.640785
- `fact_id=183308` (`A_core`) — a combined Odds Ratio of 0.468; 95% CI 0.275-0.799 for the association between HCC and the use of metformin. doi=10.1016/j.aohep.2019.10.005
- `fact_id=80429` (`A_core`) — Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81) doi=10.1002/ijc.31783
- `fact_id=1110` (`A_core`) — Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95% confidence interval (CI), 0.52-0.90] doi=10.1158/1940-6207.capr-13-0424
- `fact_id=128304` (`A_core`) — metformin alone to 0.76 (0.58–0.98) doi=10.3233/jad-2011-101524
- `fact_id=2474` (`A_core`) — A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in subjects taking metformin compared with other antidiabetic drugs. doi=10.1158/1940-6207.capr-10-0157

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _Counter-evidence not classified yet._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "ac055394-e314-4394-9e8c-c41bd7a481bf",
  "title": "Metformin reduces overall and progression-free survival mortality/mortality risk in cancer patients (various tumor types)"
}